Clinical Trials

Clinical trials are research studies that test whether new medical treatments, devices or strategies  are safe and effective.

People who volunteer for clinical trials play an active role in their own health care, often gain access to experimental treatments, and help others by improving and advancing medical care.

At Providence Cancer Center, our scientists and physicians work closely together to make clinical trials a regular part of cancer care. Patients may take part in studies initiated by our translational researchers at the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute, in addition to studies sponsored by the National Cancer Institute or pharmaceutical and biotechnology companies.

Our clinical trials team works directly with physicians to identify clinical trials appropriate for their patients’ specific stage of disease.

The goals of clinical research vary from trial to trial. Generally, they are designed to:

  • Improve prevention, early diagnosis and treatment of cancer
  • Discover whether a particular drug  or medical treatment is safe and effective
  • Advance the state of scientific and medical knowledge
  • Measure and improve the quality of life for patients and their families
Find cancer clinical trials available in Oregon in the list below. You may search by keyword or condition/disease, or browse using the page numbers and arrows. Find additional trials by using the search term “Oncology Multiple Tumor Sites". To learn more about a particular trial and qualification criteria, click the trial name and then the listed contact link, or talk with your physician.

For more information about clinical trials available through Providence Cancer Center, call 503-215-2614
« Previous 12345 Next »
Viewing Page 1 of 33 | Showing Results 1 - 5 of 164

S1404, A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.

This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B works compared with pembrolizumab in treating patients...

Gary Goodman, M.D.
  • Clackamas Radiation Oncology Center
  • Oncology and Hematology Care Southeast
  • Providence Newberg Medical Center
  • Providence Portland Medical Center
  • Providence St. Vincent Medical Center
  • Providence Willamette Falls Medical Center
  • Swedish

Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients with Metastatic Melanoma

The goal of this study is to determine a safe dose of GR-MD-02 used in combination with the FDA-approved dose of ipilimumab (3 mg/kg) in patients...

Brendan Curti, M.D.
  • Oncology and Hematology Care Eastside

A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients with Stage IIIc and Stage IV Malignant Melanoma to Extend Dosing for up to 48 weeks Total

This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted...

Brendan Curti, M.D.
  • Oncology and Hematology Care Eastside

Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma

The primary objective of this study is to compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and...

Gary Goodman, M.D.
  • Swedish

Phase Ib Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

This study will employ a phase Ib design using the established dose of CAVATAK with ipilimumab in patients with advanced melanoma for whom...

Brendan Curti, M.D.
  • Oncology and Hematology Care Eastside
« Previous 12345 Next »
Viewing Page 1 of 33 | Showing Results 1 - 5 of 164